AVEO PHARMACEUTICALS INC's ticker is AVEO and the CUSIP is 053588109. A total of 46 filers reported holding AVEO PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $56,000 | -50.4% | 68,346 | -3.1% | 0.00% | – |
| Q4 2018 | $113,000 | -50.4% | 70,562 | +2.4% | 0.00% | -100.0% |
| Q3 2018 | $228,000 | +52.0% | 68,920 | +4.1% | 0.00% | 0.0% |
| Q2 2018 | $150,000 | – | 66,213 | +14078.4% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 467 | -68.2% | 0.00% | – |
| Q4 2015 | $2,000,000 | +99900.0% | 1,467 | -13.3% | 0.00% | – |
| Q3 2015 | $2,000 | -99.9% | 1,692 | 0.0% | 0.00% | – |
| Q2 2015 | $2,944,000 | +193.5% | 1,692 | +144.5% | 0.00% | – |
| Q1 2015 | $1,003,000 | +72.6% | 692 | 0.0% | 0.00% | – |
| Q4 2014 | $581,000 | -24.3% | 692 | 0.0% | 0.00% | – |
| Q3 2014 | $768,000 | -39.3% | 692 | 0.0% | 0.00% | – |
| Q2 2014 | $1,266,000 | -97.6% | 692 | -98.1% | 0.00% | – |
| Q1 2014 | $53,780,000 | -16.8% | 35,973 | +2.4% | 0.00% | – |
| Q4 2013 | $64,625,000 | -12.0% | 35,126 | -1.0% | 0.00% | – |
| Q3 2013 | $73,421,000 | -9.1% | 35,472 | +9.8% | 0.00% | – |
| Q2 2013 | $80,765,000 | – | 32,306 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greylock XI GP Limited Partnership | 584,004 | $1,068,000 | 100.00% |
| GREAT POINT PARTNERS LLC | 2,325,000 | $4,255,000 | 1.89% |
| Sarissa Capital Management LP | 2,570,759 | $4,704,000 | 1.60% |
| Deer VI & Co. LLC | 675,242 | $1,236,000 | 0.68% |
| Palo Alto Investors LP | 1,200,800 | $2,197,000 | 0.16% |
| Baupost Group | 3,829,350 | $7,008,000 | 0.11% |
| Gruss Capital Management LP | 533,253 | $976,000 | 0.05% |
| Granahan Investment Management | 676,451 | $1,238,000 | 0.04% |
| Fore Research & Management, LP | 674,200 | $1,233,000 | 0.04% |
| TFS CAPITAL LLC | 210,369 | $385,000 | 0.03% |